Targeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Miller, Miles A ^a   Moss, Marcia L ^b   Powell, Gary ^c   Petrovich, Robert ^c   Edwards, Lori ^c   Meyer, Aaron S ^a   Griffith, Linda G ^a   Lauffenburger, Douglas A ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b BioZyme Inc   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM12 PROTEIN; ADAM12 PROTEIN, HUMAN; AMPHIREGULIN; ENZYME INHIBITOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; LIGAND; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PROTEIN BINDING; RECOMBINANT PROTEIN;

ANTAGONISTS AND INHIBITORS; AUTOCRINE EFFECT; BIOLOGICAL MODEL; CELL LINE; CELL MOTION; CYTOLOGY; DRUG EFFECTS; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; GENETICS; HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

ADAM PROTEINS; ADAM12 PROTEIN; AMPHIREGULIN; ANTIBODIES, MONOCLONAL; AUTOCRINE COMMUNICATION; CELL LINE; CELL MOVEMENT; ENDOMETRIOSIS; ENDOMETRIUM; ENZYME INHIBITORS; FEMALE; HEPARIN-BINDING EGF-LIKE GROWTH FACTOR; HUMANS; LIGANDS; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; PROTEIN BINDING; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 84945218019     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15150     Document Type: Article

References (65)

1. Hickinson, D. M. et al. Identifcation of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to geftinib. Clin Transl Sci 2, 183-192 (2009).
2. Yonesaka, K. et al. Autocrine production of amphiregulin predicts sensitivity to both geftinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 14, 6963-6973 (2008).
3. Wilson, T. R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
4. Wilson, T. R., Lee, D. Y., Berry, L., Shames, D. S. & Settleman, J. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 20, 158-172 (2011).
5. Kenny, P. A. & Bissell, M. J. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 117, 337-345 (2007).
6. Hatakeyama, H. et al. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One 5, e12702 (2010).
7. Witters, L. et al. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res 68, 7083-7089 (2008).
8. Moss, M. L. et al. The ADAM10 prodomain is a specifc inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. J Biol Chem 282, 35712-35721 (2007).
9. Rios-Doria, J. et al. A monoclonal antibody to ADAM17 inhibits tumor growth by inhibiting EGFR and non-EGFR mediated pathways. Mol Cancer Ter 14, 1-13 (2015).
10. Caiazza, F. et al. Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour efects in triple-negative breast cancer cells. Br J Cancer 112, 1895-1903 (2015).
11. Kopitz, C. et al. Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res 67, 8615-8623 (2007).
12. Schelter, F. et al. Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. Clin Exp Metastasis 28, 793-802 (2011).
13. Miller, M. A. et al. ADAM-10 and-17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling. Proc Natl Acad Sci USA 110, E2074-E2083 (2013).
14. Adams, T. E. et al. A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo. Growth Factors 27, 141-154 (2009).
15. Lindzen, M. et al. A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis. Oncogene 31, 3505-3515 (2012).
16. Forsten, K. E. & Laufenburger, D. A. Autocrine ligand binding to cell receptors. Mathematical analysis of competition by solution "decoys". Biophys J 61, 518-529 (1992).
17. Forsten, K. E. & Laufenburger, D. A. Interrupting autocrine ligand-receptor binding: comparison between receptor blockers and ligand decoys. Biophys J 63, 857-861 (1992).
18. Zeitvogel, A., Baumann, R. & Starzinski-Powitz, A. Identifcation of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model. Am J Pathol 159, 1839-1852 (2001).
19. Sanders, J. M., Wampole, M. E., Takur, M. L. & Wickstrom, E. Molecular determinants of epidermal growth factor binding: a molecular dynamics study. PLoS One 8, e54136 (2013).
20. Taipale, J. & Keski-Oja, J. Growth factors in the extracellular matrix. FASEB J 11, 51-59 (1997).
21. Higashiyama, S., Abraham, J. A. & Klagsbrun, M. Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol 122, 933-940 (1993).
22. Hieda, M. et al. Membrane-anchored growth factor, HB-EGF, on the cell surface targeted to the inner nuclear membrane. J Cell Biol 180, 763-769 (2008).
23. Hieda, M. et al. The cytoplasmic tail of heparin-binding EGF-like growth factor regulates bidirectional intracellular trafcking between the plasma membrane and ER. FEBS Open Bio 2, 339-344 (2012).
24. Chen, C. H. et al. Multiplexed protease activity assay for low-volume clinical samples using droplet-based microfuidics and its application to endometriosis. J Am Chem Soc 135, 1645-1648 (2013).
25. Beste, M. T. et al. Molecular network analysis of endometriosis reveals a role for c-Jun-regulated macrophage activation. Sci Transl Med 6, 222ra16 (2014).
26. Miller, M. A. et al. Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities. Integr Biol (Camb) 3, 422-438 (2011).
27. Bartsch, J. W. et al. Tumor necrosis factor-alpha (TNF-alpha) regulates shedding of TNF-alpha receptor 1 by the metalloprotease-disintegrin ADAM8: evidence for a protease-regulated feedback loop in neuroprotection. J Neurosci 30, 12210-12218 (2010).
28. Moss, M. L. et al. ADAM9 inhibition increases membrane activity of ADAM10 and controls alpha-secretase processing of amyloid precursor protein. J Biol Chem 286, 40443-40451 (2011).
29. Loechel, F., Overgaard, M. T., Oxvig, C., Albrechtsen, R. & Wewer, U. M. Regulation of human ADAM 12 protease by the prodomain. Evidence for a functional cysteine switch. J Biol Chem 274, 13427-13433 (1999).
30. Wewer, U. M. et al. ADAM12 is a four-leafed clover: the excised prodomain remains bound to the mature enzyme. J Biol Chem 281, 9418-9422 (2006).
31. Joslin, E. J., Opresko, L. K., Wells, A., Wiley, H. S. & Laufenburger, D. A. EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation. J Cell Sci 120, 3688-3699 (2007).
32. Joslin, E. J. et al. Structure of the EGF receptor transactivation circuit integrates multiple signals with cell context. Mol Biosyst 6, 1293-1306 (2010).
33. DeWitt, A. et al. Afnity regulates spatial range of EGF receptor autocrine ligand binding. Dev Biol 250, 305-316 (2002).
34. DeWitt, A. E., Dong, J. Y., Wiley, H. S. & Laufenburger, D. A. Quantitative analysis of the EGF receptor autocrine system reveals cryptic regulation of cell response by ligand capture. J Cell Sci 114, 2301-2313 (2001).
35. Kuzmic, P., Moss, M. L., Kofron, J. L. & Rich, D. H. Fluorescence displacement method for the determination of receptor-ligand binding constants. Anal Biochem 205, 65-69 (1992).
36. Yoshioka, J. et al. Cardiomyocyte hypertrophy and degradation of connexin43 through spatially restricted autocrine/paracrine heparin-binding EGF. Proc Natl Acad Sci USA 102, 10622-10627 (2005).
37. Tschumperlin, D. J. et al. Mechanotransduction through growth-factor shedding into the extracellular space. Nature 429, 83-86 (2004).
38. Ushikoshi, H. et al. Local overexpression of HB-EGF exacerbates remodeling following myocardial infarction by activating noncardiomyocytes. Lab Invest 85, 862-873 (2005).
39. Nickerson, N. K., Mill, C. P., Wu, H. J., Riese, D. J. & Foley, J. Autocrine-derived epidermal growth factor receptor ligands contribute to recruitment of tumor-associated macrophage and growth of basal breast cancer cells in vivo. Oncol Res 20, 303-317 (2013).
40. Guzman, M. J., Shao, J. & Sheng, H. Pro-neoplastic efects of amphiregulin in colorectal carcinogenesis. J Gastrointest Cancer 44, 211-221 (2013).
41. Sternlicht, M. D. et al. Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development 132, 3923-3933 (2005).
42. Bavik, C. et al. The gene expression program of prostate fbroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res 66, 794-802 (2006).
43. Sahin, U. et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164, 769-779 (2004).
44. Kurisaki, T. et al. Phenotypic analysis of Meltrin alpha (ADAM12)-defcient mice: involvement of Meltrin alpha in adipogenesis and myogenesis. Mol Cell Biol 23, 55-61 (2003).
45. Asakura, M. et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8, 35-40 (2002).
46. Roy, R. & Moses, M. A. ADAM12 induces estrogen-independence in breast cancer cells. Breast Cancer Res Treat 131, 731-741 (2012).
47. Rocks, N. et al. The metalloproteinase ADAM-12 regulates bronchial epithelial cell proliferation and apoptosis. Cell Prolif 41, 988-1001 (2008).
48. Nyren-Erickson, E. K., Jones, J. M., Srivastava, D. K. & Mallik, S. A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications. Biochim Biophys Acta 1830, 4445-4455 (2013).
49. Painter, J. N. et al. High-density fne-mapping of a chromosome 10q26 linkage peak suggests association between endometriosis and variants close to CYP2C19. Fertil Steril 95, 2236-2240 (2011).
50. Burney, R. O. et al. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology 148, 3814-3826 (2007).
51. Aghajanova, L. et al. Unique transcriptome, pathways, and networks in the human endometrial fbroblast response to progesterone in endometriosis. Biol Reprod 84, 801-815 (2011).
52. Kveiborg, M. et al. A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res 65, 4754-4761 (2005).
53. Frohlich, C. et al. ADAM12 produced by tumor cells rather than stromal cells accelerates breast tumor progression. Mol Cancer Res 9, 1449-1461 (2011).
54. Kawaguchi, N. et al. ADAM12 protease induces adipogenesis in transgenic mice. Am J Pathol 160, 1895-1903 (2002).
55. Masaki, M., Kurisaki, T., Shirakawa, K. & Sehara-Fujisawa, A. Role of meltrin α (ADAM12) in obesity induced by high-fat diet. Endocrinology 146, 1752-1763 (2005).
56. Dufy, M. J. et al. The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin Proteomics 8, 9 (2011).
57. Friedman, S. et al. Clinical Beneft of INCB7839, a potent and selective inhibitor of ADAM10 and ADAM17, in combination with trastuzumab in metastatic HER2 Positive Breast Cancer. Cancer Res 69, 5056 (2009).
58. Grabowska, M. M., Sandhu, B. & Day, M. L. EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells. Cell Signal 24, 532-538 (2012).
59. Tape, C. J. et al. Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci USA 108, 5578-5583 (2011).
60. Basu, B. et al. Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain. Int J Biochem Cell Biol 44, 393-403 (2012).
61. Kveiborg, M. et al. Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2). Biochem J 430, 79-86 (2010).
62. Banu, S. K., Lee, J., Starzinski-Powitz, A. & Arosh, J. A. Gene expression profles and functional characterization of human immortalized endometriotic epithelial and stromal cells. Fertil Steril 90, 927-87 (2008).
63. Spangler, J. B. et al. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci USA 107, 13252-13257 (2010).
64. Santella, A., Du, Z., Nowotschin, S., Hadjantonakis, A. K. & Bao, Z. A hybrid blob-slice model for accurate and efcient detection of fuorescence labeled nuclei in 3D. BMC Bioinformatics 11, 580 (2010).
65. Moss, M. L. & Rasmussen, F. H. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Anal Biochem 366, 144-148 (2007).